Redhill Biopharma RDHL

NAS: RDHL | ISIN: US7574681034 30/04/2025

2,205 USD (-1,12%)

(-1,12%) 30/04/2025

Grafiek Redhill Biopharma

Grafiek Redhill Biopharma

1 dag1d -1,12%
1 week1w -4,96%
1 maand1m -13,53%
3 maanden3m -62,50%
6 maanden6m -73,01%
1 jaar1j 388,91%
5 jaar5j -67,09%

Redhill Biopharma in het nieuws

Toon enkel gratis nieuws

28 april 2025 · RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107 · Persbericht

17 april 2025 · RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency · Persbericht

16 april 2025 · RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption · Persbericht

10 april 2025 · RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights · Persbericht

18 maart 2025 · RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation · Persbericht

12 maart 2025 · RedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 Results · Persbericht

9 september 2024 · RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines · Persbericht

5 september 2024 · RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement · Persbericht

3 september 2024 · New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality · Persbericht

29 augustus 2024 · RedHill Biopharma Announces First Half 2024 Business Highlights · Persbericht

Profiel Redhill Biopharma

Fabricage van farmaceutische preparaten

Gezondheidstechnologie

CEO: Dror Ben-Asher

Werknemers: 150

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe